Search

Highlights from the SWG

During 2023, the SWG:

Held a joint scientific meeting with the SWG on Myelodysplastic Syndromes and the SWG on Acute Myeloid Leukemia
Commenced work on guidelines for young MPN patients
Delivered a presentation for the American Society of Hematology (ASH) on the database…

Read more

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Highlights from the SWG

Session on thrombocytopenias and platelet function disordersFull title‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia. ’

DateThe session took place as part of the EHA 2023 Congress. This was held from June 8–11, 2023.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more